Index S&P 500
P/E 31.42
EPS (ttm) 4.86
Insider Own 0.13%
Shs Outstand 1.77B
Perf Week 0.41%
Market Cap 272.29B
Forward P/E 13.81
EPS next Y 11.06
Insider Trans -4.52%
Shs Float 1.76B
Perf Month 3.85%
Income 8.63B
PEG -
EPS next Q 2.87
Inst Own 70.90%
Short Float / Ratio 0.71% / 2.51
Perf Quarter 12.37%
Sales 56.02B
P/S 4.86
EPS this Y 2.70%
Inst Trans 0.10%
Short Interest 12.45M
Perf Half Y -1.65%
Book/sh 7.28
P/B 20.98
EPS next Y 0.03%
ROA 6.30%
Target Price 169.42
Perf Year 8.86%
Cash/sh 4.92
P/C 31.06
EPS next 5Y -4.13%
ROE 58.20%
52W Range 130.96 - 168.11
Perf YTD -5.49%
Dividend 5.92
P/FCF 10.98
EPS past 5Y 13.30%
ROI 20.50%
52W High -9.14%
Beta 0.53
Dividend % 3.88%
Quick Ratio 0.80
Sales past 5Y 15.50%
Gross Margin 70.50%
52W Low 16.63%
ATR 2.25
Employees 50000
Current Ratio 0.90
Sales Q/Q -4.90%
Oper. Margin 31.00%
RSI (14) 60.31
Volatility 1.31% 1.41%
Optionable Yes
Debt/Eq 4.74
EPS Q/Q 121.10%
Profit Margin 15.40%
Rel Volume 0.61
Prev Close 153.43
Shortable Yes
LT Debt/Eq 4.34
Earnings Jul 27 BMO
Payout 118.50%
Avg Volume 4.97M
Price 152.74
Recom 2.40
SMA20 2.13%
SMA50 3.45%
SMA200 1.81%
Volume 3,048,684
Change -0.45%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-25-23 Initiated
William Blair
Mkt Perform
Jul-14-23 Initiated
HSBC Securities
Buy
$167
Apr-05-23 Downgrade
Argus
Buy → Hold
Mar-01-23 Initiated
Guggenheim
Buy
$172
Feb-22-23 Downgrade
Wolfe Research
Outperform → Peer Perform
Feb-10-23 Upgrade
SVB Securities
Underperform → Market Perform
$135 → $153
Nov-18-22 Initiated
Credit Suisse
Outperform
$170
Nov-08-22 Downgrade
Societe Generale
Buy → Hold
Aug-01-22 Downgrade
Atlantic Equities
Overweight → Neutral
$178 → $162
May-23-22 Initiated
SVB Leerink
Underperform
$140
May-06-22 Downgrade
Daiwa Securities
Outperform → Neutral
$150
Apr-06-22 Resumed
Morgan Stanley
Overweight
$192
Feb-28-22 Downgrade
UBS
Buy → Neutral
$129 → $147
Feb-03-22 Reiterated
Goldman
Neutral
$117 → $122
Feb-03-22 Reiterated
BofA Securities
Neutral
$135 → $138
Feb-03-22 Reiterated
BMO Capital Markets
Outperform
$153 → $154
Feb-03-22 Reiterated
Barclays
Equal Weight
$133 → $150
Jan-13-22 Initiated
Redburn
Buy
Jan-12-22 Reiterated
BMO Capital Markets
Outperform
$134 → $153
Dec-09-21 Resumed
Wells Fargo
Overweight
$165
Show Previous Ratings
Sep-22-23 05:03PM
04:28PM
03:47PM
Sep-21-23 04:06PM
(Investor's Business Daily)
01:54PM
10:15AM
Loading…
10:15AM
Sep-19-23 04:18PM
(Investor's Business Daily)
Sep-18-23 05:45PM
09:00AM
09:00AM
Sep-15-23 09:33AM
09:15AM
08:32AM
Sep-14-23 05:00AM
Sep-13-23 08:12PM
11:00AM
Loading…
11:00AM
10:02AM
09:30AM
Sep-12-23 05:16PM
05:11PM
09:30AM
08:30AM
Sep-11-23 05:45PM
03:30PM
09:12AM
Sep-08-23 12:10PM
11:23AM
Sep-07-23 07:00AM
Sep-06-23 11:14AM
08:45AM
08:00AM
Loading…
08:00AM
07:03AM
01:36AM
Sep-05-23 05:45PM
09:51AM
09:00AM
Sep-02-23 07:35AM
06:55AM
Sep-01-23 09:39AM
Aug-31-23 11:10PM
11:22AM
Aug-30-23 02:26PM
(Investor's Business Daily)
01:25PM
01:25PM
11:33AM
09:00AM
Aug-29-23 05:12PM
(The Wall Street Journal)
04:07PM
(Investor's Business Daily)
02:45PM
12:25PM
10:47AM
09:45AM
09:28AM
(Investor's Business Daily)
09:21AM
Aug-28-23 08:45AM
Aug-27-23 09:47AM
Aug-26-23 06:55AM
Aug-25-23 09:59AM
09:21AM
09:00AM
Aug-24-23 12:50PM
11:03AM
10:53AM
10:42AM
Aug-23-23 04:51PM
04:22PM
Aug-22-23 03:50PM
Aug-21-23 07:24PM
12:58PM
Aug-18-23 11:38AM
Aug-17-23 08:31PM
11:43AM
08:45AM
02:00AM
Aug-15-23 05:15PM
07:58AM
07:00AM
(The Wall Street Journal)
Aug-14-23 04:03PM
(Investor's Business Daily)
08:01AM
05:50AM
Aug-12-23 06:15AM
Aug-10-23 10:00AM
Aug-09-23 10:23AM
09:24AM
Aug-08-23 05:37AM
Aug-06-23 07:01AM
Aug-04-23 12:12PM
11:36AM
08:19AM
07:28AM
Aug-03-23 09:45AM
07:15AM
07:00AM
Aug-02-23 01:40PM
11:49AM
Aug-01-23 04:45PM
01:30PM
08:45AM
05:50AM
Jul-31-23 11:09AM
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behcet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Aug 01 Sale 148.58 60,000 8,914,800 565,294 Aug 02 05:07 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Jul 31 Sale 149.15 18,500 2,759,275 625,294 Aug 02 05:07 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Apr 25 Option Exercise 144.54 6,130 886,030 41,460 Apr 27 05:00 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Apr 25 Sale 165.00 6,130 1,011,450 35,330 Apr 27 05:00 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Apr 17 Sale 161.67 7,499 1,212,338 35,330 Apr 19 05:00 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Apr 03 Option Exercise 93.50 15,002 1,402,687 57,831 Apr 05 05:00 PM Siatis Perry C EVP, GC AND SECRETARY Apr 03 Option Exercise 105.92 3,520 372,838 13,897 Apr 05 05:00 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Apr 03 Sale 160.03 15,002 2,400,770 42,829 Apr 05 05:00 PM Siatis Perry C EVP, GC AND SECRETARY Apr 03 Sale 160.00 3,520 563,200 10,377 Apr 05 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 13 Option Exercise 54.86 21,810 1,196,497 114,066 Mar 15 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 13 Sale 152.28 53,125 8,089,998 60,941 Mar 15 05:00 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Mar 01 Option Exercise 93.50 15,003 1,402,780 57,832 Mar 02 05:07 PM SALEKI-GERHARDT AZITA EVP, OPERATIONS Mar 01 Option Exercise 51.42 26,990 1,387,826 226,839 Mar 02 05:01 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 Sale 153.28 44,141 6,766,103 13,837 Mar 02 04:30 PM SALEKI-GERHARDT AZITA EVP, OPERATIONS Mar 01 Sale 154.48 36,990 5,714,215 189,849 Mar 02 05:01 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Mar 01 Sale 153.08 15,942 2,440,355 809 Mar 02 05:04 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Mar 01 Sale 155.00 15,003 2,325,465 42,829 Mar 02 05:07 PM Siatis Perry C EVP, GC AND SECRETARY Mar 01 Sale 153.08 12,135 1,857,641 10,377 Mar 02 05:06 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Feb 21 Option Exercise 105.92 15,321 1,622,800 78,000 Feb 21 06:12 PM Strom Carrie C SVP & PRES GLOBAL ALLERG AESTH Feb 21 Option Exercise 61.57 14,179 872,949 66,462 Feb 21 06:14 PM Siatis Perry C EVP, GC AND SECRETARY Feb 21 Option Exercise 93.50 7,364 688,534 39,532 Feb 22 05:00 PM Strom Carrie C SVP & PRES GLOBAL ALLERG AESTH Feb 21 Sale 151.04 28,541 4,310,771 37,921 Feb 21 06:14 PM Sorg Elaine K. SVP, US COMMERCIAL OPERATIONS Feb 21 Sale 151.04 15,321 2,314,119 62,679 Feb 21 06:12 PM Siatis Perry C EVP, GC AND SECRETARY Feb 21 Sale 151.03 7,364 1,112,178 32,168 Feb 22 05:00 PM SALEKI-GERHARDT AZITA EVP, OPERATIONS Feb 17 Option Exercise 51.42 25,000 1,285,500 258,208 Feb 21 06:13 PM SALEKI-GERHARDT AZITA EVP, OPERATIONS Feb 17 Sale 149.53 25,000 3,738,144 233,208 Feb 21 06:13 PM AUSTIN ROXANNE S Director Feb 17 Sale 150.50 10,000 1,505,000 40,705 Feb 21 06:16 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Dec 12 Option Exercise 54.86 42,370 2,324,418 56,207 Dec 14 05:06 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Dec 12 Sale 163.44 42,370 6,925,018 13,837 Dec 14 05:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite